Pfizer purchases Angiosyn, deal to close in first quarter

Share this article:
Pfizer has entered an agreement to buy the bio-tech start up Angiosyn which is working on a drug to help ward off blindness.
Pfizer is expected to make a small payment for the La Jolla, Calif., company upfront followed by additional payments totaling up to $527 million. The deal was expected to close in the first quarter of 2005.
The acquisition marks Pfizer's second biotechnology acquisition in about a year. Pfizer purchased Esperion Therapeutics, a start-up company working on treatments for high cholesterol, early last year.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.